Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-06-08T04:45:33.493Z Has data issue: false hasContentIssue false
  • English
  • Français

Central 5-HT2 antagonists: A preclinical evaluation of a therapeutic potential

Published online by Cambridge University Press:  18 September 2015

T.F. Meert  and
F. Awouters
T.F. Meert*
Affiliation:
Afdeling Neuro-Psychopharmarcologie, Janssen Research Foundation, B-2340 Beerse, België
F. Awouters
Affiliation:
Afdeling Neuro-Psychopharmarcologie, Janssen Research Foundation, B-2340 Beerse, België
*
Afd. Neuro-Psychopharmacologie Janssen Research Foundation, B-2340 Beerse, België
Get access Rights & Permissions [Opens in a new window]

Summary

A preclinical evaluation is presented of the serotonin 5-HT2 antagonists ritanserin and risperidone. Whereas ritanserin is a relative selective 5-HT2 antagonist, risperidone is a potent 5-HT2 and catecholamine antagonist. The pharmacological differences between both drugs are also observed in the drug discrimination test procedure. Using DOM, d-amphetamine and cocaine. Ritanserin was found active in animal models of anxiety using natural aversive stimuli; and in animal models of depression. Clear differences were observed between ritanserin and the benzodiazepines and between ritanserin and the tricyclic antidepressants. Risperidone was active in animal models of psychosis. Risperidone has, as opposed to classical neuroleptics such as haloperidol, less risks of inducing a dopamine D2 overblockade. Clinically, ritanserin is described as a thymostenic agent.

Risperidone is an antipsychotic with therapeutic effects on both the positive and negative symptoms of schizophrenia and with a reduced risk of extrapyramidal side-effects.

Keywords

serotonin 5-HT2-antagonistsritanserinrisperidonethymosthenicantipsychoticSerotonine 5-HT2-antagonistritanserinrisperidonethymo sthenic urnantipsychoticum
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 2 , Issue 4 , December 1990 , pp. 101 - 109
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1990

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1.Tedeschi, DH, Tedeschi, RE, Fellows, EJ. Central serotonin antagonist activity of a number of phenothiazines. Arch Int Pharmacodyn 1961; 132: 172–9.Google ScholarPubMed
2.Niemegeers, CJE, Lenaerts, FM, Artois, KSK, Janssen, PAJ. Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new ‘in vivo’ approach: the ATN-test in rats. Arch Int Pharmacodyn Ther 1977;227:238–53.Google ScholarPubMed
3.Jacobs, BL. An animal behavior model for studying central serotonergic synapses. Life Sci 1976; 19:777–86.CrossRefGoogle ScholarPubMed
4.Niemegeers, CJE, Colpaert, FC, Leysen, JE, Awouters, F, Janssen, PAJ. Mescaline-induced head-twitches in the rat: An in vivo method to evaluate serotonin S2 antagonists. Drug Dev Res 1983; 3: 123–35.CrossRefGoogle Scholar
5.Awouters, F, Niemegeers, CJE, Megens, AAHP, Meert, TF, Janssen, PAJ. The pharmacological profile of ritanserin, a very specific central serotonin-S2 antagonist. Drug Dev Res 1988;15:61–73.CrossRefGoogle Scholar
6.Janssen, PAJ, Niemegeers, CJE, Awouters, F, Schellekens, KHL, Megens, AAHP, Meert, TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol exp Ther 1988; 244: 685–93.Google ScholarPubMed
7.Freedman, DX. On the use and abuse of LSD. Arch gen Psychiat 1968;18:330–47.CrossRefGoogle ScholarPubMed
8.Van Praag, HM. Serotonerge mechanismen in de Pathogenese van schizofrene psychosen. Acta neuropsychiat 1989; 1:28–33.Google Scholar
9.Geyer, MA, Braff, DL. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull 1987; 13: 643–68.CrossRefGoogle ScholarPubMed
10.Beamish, P, Kiloh, LG. Psychosis due to amphetamine consumption. J Ment Sci 1960; 106:337–43.CrossRefGoogle ScholarPubMed
11.Fischman, MW, Schuster, CR, Resnekov, L, Shick, JFE, Krasnegor, NA, Fennell, W, Freedman, DX. Cardiovascular and subjective effects of intravenous cocaine administration in humans. Arch Gen Psychiat 1976;33:983–9.CrossRefGoogle ScholarPubMed
12.Colpaert, FC, Niemegeers, CJE, Janssen, PAJ. A drug discrimination analysis of lysergic acid diethylamide (LSD): In vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist. J Pharmacol exp Ther 1982; 221:206–14.Google ScholarPubMed
13.Colpaert, FC, Meert, TF, Niemegeers, CJE, Janssen, PAJ. Behavioral and 5-HT antagonist effects of ritanserin: A pure and selective antagonist of LSD discrimination in rat. Psychopharmacol 1985; 86:45–54.CrossRefGoogle ScholarPubMed
14.Meert, TF, De Haes, P, Janssen, PAJ, Risperidone (R 64 766) a potent and complete LSD antagonist in drug discrimination by rats. Psychopharmacol 1989; 97:206–12.CrossRefGoogle ScholarPubMed
15.Meert, TF, De Haes, PLAJ, Vermote, PCM, Janssen, PAJ. A pharmacological validation of ritanserin and risperidone in the drug discrimination test procedure in the rat. Drug Dev Res 1990a; in press.Google Scholar
16.Meert, TF, Janssen, PAJ. The psychopharmacology of ritanserin: Comparison with chlordiazepoxide. Drug Dev Res 1989; 18: 119–44.CrossRefGoogle Scholar
17.Meert, TF, Awouters, F, Melis, WJC, Janssen, PAJ. Ritanserin reduces alcohol preference and alcohol intake in rats given the choice between 3% alcohol and water. Life Sci Adv 1990b; in press.Google Scholar
18.Megens, AAHP, Awouters, FHL, Niemegeers, CJE. Interaction of haloperidol and risperidone (R 64 766) with amphetamine-induced motility changes in rats. Drug Dev Res 1989; 17:23–33.CrossRefGoogle Scholar
19.Ellenbroek, BA, Peeters, BW, Honig, WM, Cools, AR. The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacol 1987; 93:343–8.CrossRefGoogle Scholar
20.Ellenbroek, BA. Animal models for schizophrenia and neuroleptic drug action. Doctoral thesis, University of Nijmegen, The Netherlands, 1988.Google Scholar
21.Declerck, AC, Wauquier, A, Van der Ham-Veltman, PHM, Gelders, Y. Increase in slow-wave sleep in humans with the serotonin-S2antagonist ritanserin. Curr Ther Res 1987; 41:427–32.Google Scholar
22.Idzikowski, C, Mills, EJ, Glennard, R. 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. Brain Res 1986; 378: 164–8CrossRefGoogle ScholarPubMed
23.Janssen, PAJ. The relevance of pharmacological studies to sleep research in psychiatry. Pharmacopsychiat 1988;21: 33–7.CrossRefGoogle ScholarPubMed
24.Meert, TF, Awouters, F. Serotonin 5-HT2 antagonists: A preclinical evaluation of possible therapeutic effects. In: C, Idzikowski and P, Cowen, eds. Serotonin, sleep and mental disorders. Wrightson Biomedical Publishing LTD, 1990.Google Scholar
25.Reyntjens, A, Gelders, YG, Hoppenbrouwers, M-LJA, Vanden Bussche, G. Thymosthenic effects of ritanserin (R 55 667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 1986; 8:205–11.CrossRefGoogle Scholar